Financial Performance - The company's operating revenue for Q1 2024 reached ¥955,017,184.55, representing a year-on-year increase of 14.70%[3] - The net profit attributable to shareholders was ¥197,665,895.38, reflecting a growth of 5.36% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 35.67%, primarily due to revenue growth and improved gross margin[6] - Net profit for Q1 2024 was ¥203,220,964.27, up from ¥189,479,862.57 in Q1 2023, reflecting a growth of 7.4%[18] - Operating profit for Q1 2024 was ¥240,223,939.49, compared to ¥228,855,644.72 in Q1 2023, indicating an increase of 5.4%[17] - Total operating revenue for Q1 2024 reached ¥955,017,184.55, an increase of 14.7% compared to ¥832,651,815.62 in Q1 2023[17] Cash Flow - The net cash flow from operating activities was ¥59,465,024.89, with no applicable year-on-year comparison[3] - Cash flow from operating activities for Q1 2024 was ¥59,465,024.89, a significant improvement from a negative cash flow of -¥90,728,201.78 in Q1 2023[21] - In Q1 2024, the net cash flow from operating activities was ¥457,172,228.65, a decrease of 21.5% compared to ¥582,847,645.15 in Q1 2023[32] - Total cash inflow from operating activities was ¥918,254,814.69, down from ¥1,064,673,790.92 in the same period last year[32] - The cash outflow from operating activities totaled ¥461,082,586.04, slightly lower than ¥481,826,145.77 in Q1 2023[32] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,012,168,095.91, an increase of 3.78% from the end of the previous year[3] - The company's total liabilities were RMB 968,729,828.24, slightly up from RMB 959,617,984.37, showing a marginal increase of about 1.2%[14] - The total assets as of March 31, 2024, amounted to ¥5,127,286,083.56, compared to ¥4,415,931,097.09 at the end of 2023, indicating a growth of 16.1%[26] - The total liabilities increased to ¥1,020,382,685.53 in Q1 2024 from ¥516,808,446.18 in Q4 2023, showing a significant rise of 97.5%[26] Shareholder Equity - The equity attributable to shareholders increased to ¥3,912,993,199.93, marking a growth of 4.68% compared to the previous year-end[3] - The basic and diluted earnings per share were both ¥0.46, up by 4.55% year-on-year[3] - The company's total equity increased to ¥4,106,903,398.03 in Q1 2024 from ¥3,899,122,650.91 in Q4 2023, reflecting a growth of 5.3%[27] Research and Development - Research and development expenses for Q1 2024 were ¥16,788,255.40, slightly down from ¥17,029,168.21 in Q1 2023, a decrease of 1.4%[17] - Research and development expenses for Q1 2024 were ¥13,501,286.16, slightly down from ¥14,861,949.84 in Q1 2023, a decrease of 9.1%[29] Inventory and Receivables - The company's inventory rose to RMB 291,254,529.39 from RMB 273,477,215.97, reflecting an increase of about 6.5%[12] - The accounts receivable decreased slightly to RMB 232,112,298.14 from RMB 246,372,810.49, a decline of approximately 5.8%[12] - The company reported a decrease in inventory to ¥86,020,519.70 from ¥98,129,648.81, a decline of 12.3%[25] Government Subsidies - The company received government subsidies amounting to ¥7,567,790.68, which positively impacted the financial results[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,231[8]

马应龙（600993.SH） 渠道优化扰动业绩，经营现金流改善 事件：2023 年公司实现营业收入 31.37 亿元，同比减少 11.20%；归母净利 润 4.43亿元，同比减少 7.38%，扣非归母净利润 3.52亿元，同比减少 23.61%。 其中 23Q4 公司实现营收 6.91 亿元，同比减少 7.60%；归母净利润 0.25 亿 元，同比减少 60.22%，扣非归母净利润亏损 0.08 亿元。 规模效应减弱拉低毛利率，投资净收益改善利润。23 年公司主营业务毛利率 41.44%，同比下降 0.53pct，其中医药工业、商业及服务板块毛利率分别变 动-0.56%、-0.60%、2.42%，其中工业毛利率下降主要原因是生产量减少， 单位生产成本略有上升；销售费用率、管理费用率、研发费用率分别为 22.80%、3.51%、2.20%，同比分别变动 0.7pct、0.53pct、-0.01pct；投资 净收益同比增加 5 千万，最终净利率 14.40%，同比提升 0.8pct。其中，23Q4 毛利率 36.71%，销售费用率、管理费用率、研发费用率分别为 30.90%、 4.05%、2.99%。 24 年继 ...

证券代码：600993 证券简称：马应龙 公告编号：临 2024-007 马应龙药业集团股份有限公司 剂型：散剂 规格：本品为复方制剂，每袋含：聚乙二醇 4000 64g，硫酸钠 5.7g，氯化钠 1.46g，氯化钾 0.75g，碳酸氢钠 1.68g 注册分类：化学药品 4 类 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 马应龙药业集团股份有限公司（以下简称"公司"或"本公司"）近日收到 国家药品监督管理局核准签发的复方聚乙二醇电解质散（Ⅲ）（以下简称"该药 品"）《药品注册证书》（证书编号：2024S00546），现就相关情况公告如下： 一、药品的基本情况 药品名称：复方聚乙二醇电解质散（Ⅲ） 药品注册标准编号：YBH04902024 处方药/非处方药：处方药 上市许可持有人：马应龙药业集团股份有限公司 生产企业：马应龙药业集团股份有限公司 药品批准文号：国药准字 H20243467 药品批准文号有效期：至 2029 年 04 月 10 日 审批结论：根据《中华人民共和国药品管理法》及有关规定 ...

数据来源:wind, 西南证券签理 [Table_StockInfo] 2024 年 04 月 13 日 证券研究报告•2023 年年报点评 当前价：24.87 元 马 应 龙（600993）医药生物 目标价：——元（6 个月） [Table_Summary 事件：马应龙发布] 2023 年年报，2023 年公司实现营收 31.4 亿元，同比下滑 11.2%；实现归母净利润 4.4 亿元，同比下滑 7.4%；实现扣非归母净利润 3.5 亿元，同比下滑 23.6%。 医药商业不断探索新模式，业务结构持续优化。医药商业业务是公司传统业务， 2023 年持续优化业务结构，实现收入 10.9亿元（-19.7%）。目前，公司医药商 业板块整合线下实体药店、网上药店、医药物流等业务，由传统药品生产企业 向肛肠健康方案提供商转型升级，促进线上线下全渠道运营。 1 [Table_QuotePic] 相对指数表现 的位证 1.1 四百年传统制药技艺,老字号新时代焕发活力 图 1:马应龙股权结构(截至2023年年报) 中国宝安集团股份有限公司 式汉商贸集团有限公司 其他 5.21% 29.27% 65.52% 马应龙药业集团殷份 ...

流通股本（万股） 43,030.70 最近一年走势 市场数据 2024/04/12 2023 年经营性现金流大幅提升，应收账款恢复良性。截至报告期末， 马应龙母公司应收账款及应收票据金额较期初下降 35.83%，存货金 额较期初减少 22.41%，经营性现金流净额同比大幅提升。 当前价格（元） 24.87 52 周价格区间（元） 20.20-32.20 相关报告 中药Ⅱ*周小刚》——2022-11-13 行业竞争加剧；治痔类产品终端动销不及预期；医药政策风险等。 道增长稳健，眼霜重塑马应龙品牌活力 （买入）* 证券研究报告 保证相关的建议不会发生任何变更。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断， 本报告所指的证券或投资标的的价格、价值及投资收入可能会波动。在不同时期，本公司可发出与本报告所载 资料、意见及推测不一致的报告。报告中的内容和意见仅供参考，在任何情况下，本报告中所表达的意见并不 构成对所述证券买卖的出价和征价。本公司及其本公司员工对使用本报告及其内容所引发的任何直接或间接损 失概不负责。本公司或关联机构可能会持有报告中所提到的公司所发行的证券头寸并进行交易，还可能为这些 公司 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥3.14 billion, a decrease of 11.20% compared to ¥3.53 billion in 2022[2]. - Net profit attributable to shareholders for 2023 was approximately ¥443.25 million, down 7.38% from ¥478.57 million in 2022[2]. - The net profit after deducting non-recurring gains and losses was approximately ¥352.37 million, a decrease of 23.61% from ¥461.28 million in 2022[2]. - Basic earnings per share for 2023 were ¥1.03, a decrease of 7.21% from ¥1.11 in 2022[5]. - The weighted average return on net assets decreased by 2.04 percentage points to 12.31% in 2023, down from 14.35% in 2022[8]. - The pharmaceutical industry segment experienced a revenue decline of 11.52% due to channel adjustments and inventory optimization[4]. - The pharmaceutical industry segment reported main business revenue of 1.834 billion yuan, a decline of 11.52% year-on-year[19]. - The pharmaceutical commercial segment's main business revenue was 1.088 billion yuan, down 19.67% year-on-year[23]. - The medical services segment saw main business revenue of 345 million yuan, an increase of 33.28% year-on-year[21]. - The company reported a total revenue of 129,210.77 million RMB in the treatment of hemorrhoids, with a gross margin of 71.08%, reflecting a year-over-year decrease of 13.18% in revenue and a decrease of 10.06% in cost[100]. - The gross margin for the pharmaceutical industrial segment was 64.55%, a decrease of 0.56 percentage points compared to the previous year[200]. Cash Flow and Assets - The net cash flow from operating activities increased by 76.70% to approximately ¥604.07 million, compared to ¥341.85 million in 2022[2]. - The net cash flow from operating activities for the reporting period was ¥604,065,441.30, an increase of 76.70% compared to ¥341,852,836.66 in the same period last year, primarily due to enhanced cash flow management and increased cash collection efforts[83]. - The net cash flow from investing activities was ¥448,271,219.58, a significant improvement from a negative cash flow of ¥618,760,257.44 in the previous year, mainly due to an increase in the redemption of financial products[83]. - The net cash flow from financing activities decreased to -¥579,164,791.21 from ¥178,177,440.46, a decline of 425.05%, attributed to reduced borrowings and repayment of previous loans[83]. - The company's total assets decreased by 5.08% to approximately ¥4.83 billion, down from ¥5.09 billion in 2022[2]. - The company's cash and cash equivalents as of December 31, 2023, amounted to ¥137,572,879.02, down from ¥153,788,092.01 on December 31, 2022, primarily due to bank acceptance bill guarantees and other deposits[86]. Market and Product Development - The company launched over 80 new health products and achieved a 15% year-on-year increase in sales revenue for the Ma Yinglong Baobao series products[20]. - The company is actively expanding its internet medical services and seeking development opportunities in the health industry, focusing on a diversified service model[46]. - The company is focusing on drug development in the core areas of anorectal and lower gastrointestinal tract, with a pipeline that includes both chemical and traditional Chinese medicine products[105]. - The company is expanding its health business, focusing on areas such as anal health, ophthalmology, and skin health, with over 100 approved pharmaceutical products[184]. - The company has established a chain of proctology hospitals in cities like Wuhan and Beijing, aiming to integrate clinical treatment and research[193]. - The company is focusing on enhancing compliance and risk management through the establishment of a legal compliance department[29]. - The company has implemented strategies to enhance market expansion and product development, particularly in the field of hemorrhoid treatment[95]. - The company is actively pursuing research and development to mitigate risks associated with long product development cycles and high investment costs in pharmaceuticals[165]. Strategic Initiatives - The company established a strategic planning department to enhance market planning capabilities and reorganized its product manufacturing headquarters to improve operational control[29]. - The company is committed to compliance and has adapted to the ongoing anti-corruption measures in the pharmaceutical industry, which are expected to accelerate compliance construction[71]. - The company aims to enhance its operational quality by innovating its business model and upgrading its marketing system in the health sector[161]. - The company has established advanced production facilities, including three automatic batching systems and eleven industrial robots, and has been recognized as a "2023 Smart Manufacturing Demonstration Factory" by the Ministry of Industry and Information Technology[178]. - The company is committed to improving its environmental protection measures in response to stricter regulations and increasing social awareness regarding environmental issues[170]. Intellectual Property and Brand Value - The company obtained 15 patent authorizations in 2023, including 7 invention patents and registered 112 new trademarks, enhancing its intellectual property portfolio[29]. - The brand value of the company has reached 52.187 billion RMB, maintaining its position as a leading brand in the hemorrhoid treatment sector for 20 consecutive years[117]. - The company emphasizes a brand management strategy to enhance core competitiveness and customer loyalty, integrating social resources to meet customer needs[117]. Industry Trends and Challenges - In 2023, the pharmaceutical industry in China saw a decline in key economic indicators, with the total revenue of large-scale enterprises dropping by 4% to CNY 2,955.25 billion and profits decreasing by 16.2% to CNY 412.72 billion[30]. - The average price reduction for drugs in the national centralized procurement in 2023 was 57%, with specific batches seeing reductions of 56% and 58% respectively[41]. - The outpatient management policies for retail pharmacies were implemented in 2023, encouraging the integration of outpatient services[39]. - The company anticipates that the traditional Chinese medicine industry will accelerate due to supportive government policies and initiatives[149]. - The company has conducted epidemiological surveys to identify opportunities in the anorectal health market, indicating a high prevalence of related conditions but low treatment rates, suggesting significant growth potential[181].

马应龙药业集团股份有限公司 审计报 告 众环审字(2024) 0101256号 家 II 起始页码 审计报告 | 财务报表 | | | --- | --- | | 合并资产负债表 | | | 合并利润表 | ന | | 合并现金流量表 | ব | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 9 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | T T 审计 报告 众环审字(2024)0101256 号 马应龙药业集团股份有限公司全体股东: 一、审计意见 我们审计了马应龙药业集团股份有限公司(以下简称"马应龙公司")财务报表,包括 2023 年 12 月 31 日的合并及公司资产负债表,2023 年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 四、其他信息 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 马应龙公司 2023年 12月 31日合并及公司的财务状况以及 2023年度合并及公司的经营成果 和现金流量。 关键审计事项是我们根据职业判断,认为 ...

2023年度 环境、社会和治理（ ESG）报告 五 龙马精神 健康人生 2023年度 环境、社会和治理（ ESG）报告 目 录 四 环境篇：绿色为先，共绘绿水青山 1、强化环境管理 2、规范排放物管理 3、优化能源与资源消耗 4、践行绿色环保理念 关于本报告 一 P01 二 走进马应龙 P03 经营篇：坚守匠心，共创卓越服务 P21 1、产品创新与升级 六 治理篇：开放透明，共铸发展基石 P37 社会篇：人本关怀，共建美好生活 P45 P61 展望2024 附录 七 P73 P75 三 1、公司简介 2、我们的2023 3、可持续发展管理 4、专题：数字革新，智能转型，构筑智慧生产典范 2、保障产品质量与安全 3、提升医疗可及 4、延伸服务触角 1、坚持党建引领 2、规范公司治理 3、维护投资者权益 4、合规与风险管理 5、恪守商业道德 1、保障员工权益 2、助力员工发展 3、携手合作共赢 4、投身社会公益 2023年度环境、社会和治理（ ESG）报告 一 关于本报告 本报告旨在真实反映马应龙药业集团股份有限公司（以下简称"马应龙""我们"或"公 司"）2023年度在环境、社会及治理方面的理念、方针、行动和进 ...

马应龙药业集团股份有限公司 2023 年度审计委员会工作报告 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《上 市公司治理准则》、《上海证券交易所股票上市规则》、《上海证券交易 所上市公司自律监管指引第 1 号-规范运作》等法律法规以及《公司 章程》、《审计委员会议事规则》等有关规定，我们作为马应龙药业集 团股份有限公司（以下简称"马应龙"或"公司"）第十一届董事会 审计委员会成员，现就 2023 年履职情况报告如下： 一、审计委员会基本情况 公司董事会审计委员会成员共有 3 名，分别为：独立董事齐珺女 士、独立董事毛鹏先生和董事黄其龙先生，其中齐珺女士为主任委员。 二、审计委员会年度会议召开情况 2023 年，公司审计委员会共计召开 5 次会议，听取经营层汇报、 对公司财务报告、内部控制实施、内外部审计师开展工作等事项进行 督导和审查，闭会期间全体委员实时关注公司生产经营情况，加强与 管理层沟通交流，确保公司各项运作符合法规和监管要求。会议详细 情况如下： | 召开日期 | | 会议内容 | 重要意见和建议 | | --- | --- | --- | --- | | 2023 | 年 | 听取 ...

关于马应龙药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：马应龙药业集团股份有限公司 审计单位：中审众环会计师事务所（特殊普通合伙） 联系电话：027-87291519 于马应龙药业集团股份有限公司 占用及其他关联资金往来情况汇 E E Z T 的 sun a 多来告 众环专字(2024) 0100441 号 马应龙药业集团股份有限公司全体股东: 我们接受委托,在审计了马应龙药业集团股份有限公司(以下简称"马应龙公司")2023 年 12 月 31 日合并及公司的资产负债表,2023 年度合并及公司的利润表、合并及公司的现 金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2023 年度非经营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇总表")进 行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号 -- 上市公 司资金往来、对外担保的监管要求》的规定,编制和披露汇总表、提供真实、合法、完整的 审核证据是马应龙公司管理层的责任,我们的责任是在执行审核工作的基础 ...